Microarrays and multiplexing

Akoya Biosciences launches panels for spatial biomarker discovery and validation

The PhenoCode Signature Panels are a hybrid of the company’s legacy Codex and Opal assays, and, when combined with the PhenoImager platforms, enable spatial phenotyping workflow, Akoya said.

November 8, 2022

QuantuMDx inks distribution agreement with Menarini

According to the agreement, Menarini will handle the distribution and marketing of the Q-POC platform, COVID assay, and QuantuMDx’s SARS-CoV-2/Flu A/B/RSV Respiratory Panel test in the U.K. and France.

November 2, 2022

Natera announces results for kidney test performance in predicting antibody mediated rejection

The Prospera test leverages Natera’s core single-nucleotide-based massively multiplexed PCR technology to identify allograft rejection noninvasively without the need for prior donor or recipient genotyping.

October 4, 2022

AMP 2021 meeting puts spotlight back on cancer

Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.

November 22, 2021

PathogenDx nabs CE-IVD Mark for DetectX-Rv test

DetectX-Rv will now be available for sale and distribution to qualified laboratories across the European Union. DetectX-Rv's microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV-2 within three hours after RNA extraction.

July 21, 2021

Most Popular

Quest launches long-COVID testing panels for consumers

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing

RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target

Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux

Patients prefer immediate test results, even when the news is bad

Quest Diagnostics offers suite of services for transplant patients and living donors